UNSPSC 51332512: Moperone

This classification denotes an anxiolytic with the molecular formula C22H26FNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OU730881W5, chemically known as 4-fluoro-4-(4-hydroxy-4-p-tolylpiperidino)butyrophenone, hydrochloride but generally known as moperone, which bears US NIH Compound Identifier 4249. European Medicines Agency schedules Moperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09057MIG.

UNSPSC 51332512 Moperone, a Commodity code, appears in state and local procurement records alongside solicitations for naloxone, safe drug deactivation systems, generic pharmaceuticals, and over-the-counter products—suggesting the code's nominal scope may not align closely with what is actually being bought. State and local issuers under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work being solicited ranges from emergency opioid-reversal supplies (naloxone) and drug destruction systems for community health programs to broader generic pharmaceutical and OTC product supply agreements serving multiple government facilities. Issuing bodies reflect a mix of single-jurisdiction health initiatives and multi-state cooperative purchasing arrangements designed to leverage scale across participating jurisdictions.

Recent activity appears concentrated in Florida and Minnesota, with ancillary procurement intelligence gathering in Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Minnesota Department of Administration, on behalf of MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program serving self-insured state agencies and employee health plans. The code shows limited but dispersed activity; the mismatch between the code's nominal name and the pharmaceutical and emergency medical supply purchases actually posted suggests either miscoding by issuers or that this Commodity code does not serve as a primary classification vehicle for state and local pharmaceutical procurement.